27 дек. 2023 г. · In the CHANCE trial, dual antiplatelet therapy led to a risk of recurrent stroke that was 3.5 percentage points lower than the risk with ...

27 апр. 2021 г. · Although there was no significant increase in the risk of hemorrhagic stroke, DAPT was associated with an increased risk of major bleeding. The ...

17 сент. 2022 г. · From the literature review, the use of DAPT in stroke patients appears safe and useful in at least two acute conditions, i.e., non-cardioembolic ...

The DAPT group had a significant reduction in the 90-day stroke rate (8.2 vs. 11.7%) and no differences in the rates of moderate or severe hemorrhage and ...

27 июн. 2023 г. · The choice of DAPT was based on the CHANCE and POINT studies, which demonstrated the superiority of DAPT to aspirin alone in acute minor stroke.

8 апр. 2020 г. · POINT showed that DAPT reduced a composite of stroke, myocardial infarction, or vascular death at 90 days, but patients suffered increased ...

4 янв. 2024 г. · The absolute risk reduction for ischemic stroke with DAPT compared with aspirin was nearly 4-fold higher (2.80% versus 0.76%; number needed to ...

16 мая 2024 г. · Importance Dual antiplatelet therapy (DAPT) appears to be an effective treatment option for minor (nondisabling) acute ischemic stroke.

8 янв. 2024 г. · The stroke rate within 90 days was 7.3% with DAPT vs. 9.2% with aspirin alone, a significant difference.

10 янв. 2024 г. · The INSPIRES trial demonstrated a reduction in 90-day recurrent stroke (ischemic or hemorrhagic) associated with clopidogrel-based DAPT vs.